ADC Therapeutics Overview

  • Founded
  • 2011

Founded
  • Status
  • Public

  • Employees
  • 312

Employees
  • Stock Symbol
  • ADCT

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $10.30

  • (As of Friday Closing)

ADC Therapeutics General Information

Description

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NYS
Primary Office
  • Biopole
  • Route de la Corniche 3B
  • 1066 Epalinges
  • Switzerland
+41 021 000 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ADC Therapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$10.30 $8.12 $5.52 - $32.00 $791M 76.8M 303K -$2.43

ADC Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 304,420 1,176,793 2,074,624
Revenue 93,946 33,917 0 2,340
EBITDA (194,868) (230,601) (239,681) (116,353)
Net Income (186,965) (230,026) (246,290) (116,484)
Total Assets 520,463 617,972 513,692 137,682
Total Debt 110,953 139,698 115,081 5,031
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ADC Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ADC Therapeutics‘s full profile, request access.

Request a free trial

ADC Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore ADC Therapeutics‘s full profile, request access.

Request a free trial

ADC Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of a
Drug Discovery
Epalinges, Switzerland
312 As of 2021
00.000
00000000 00.000

000000

smod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerc
0000 000000000
Cambridge, MA
0000 As of 0000
00.000
000000000 00.000

000000

pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit
0000 000000000
Bothell, WA
0000 As of 0000
00.000
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ADC Therapeutics Competitors (83)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BeiGene Formerly PE-Backed Cambridge, MA 0000 00.000 000000000 00.000
000000 Formerly VC-backed Bothell, WA 0000 00.000 000000&0
000000000 00000000 Formerly VC-backed San Francisco, CA 000 00000 000000&0 00000
00000000 000000000 Formerly VC-backed South San Francisco, CA 00 00000 000000000 00000
0000000 Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
You’re viewing 5 of 83 competitors. Get the full list »

ADC Therapeutics Patents

ADC Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202012161-D0 Combination therapy Ceased 05-Aug-2020 00000000000
US-20220033508-A1 Anti-il13r alpha2 antibodies Pending 31-Jul-2020 00000000000
GB-202011993-D0 Anti-il 13ra2 antibodies Ceased 31-Jul-2020 00000000000
US-20200129637-A1 Combination therapy with an anti-axl antibody-drug conjugate Pending 20-Apr-2017 00000000000
AU-2018253948-A1 Combination therapy with an anti-axl antibody-drug conjugate Pending 20-Apr-2017 C07K16/2818
To view ADC Therapeutics’s complete patent history, request access »

ADC Therapeutics Executive Team (24)

Name Title Board Seat Contact Info
Jennifer Creel Chief Financial Officer, Finance
David Gilman Chief Strategy Officer & Chief Business Officer
Richard Warburg Ph.D Managing Director
Robert Schmidt Chief Accounting Officer, Accounting & Controller, Finance
Susan Romanus Chief Compliance Officer, Legal
You’re viewing 5 of 24 executive team members. Get the full list »

ADC Therapeutics Board Members (14)

Name Representing Role Since
Barrie Ward Ph.D Self Board Member 000 0000
Jacques Theurillat Self Board Member 000 0000
Michael Forer ADC Therapeutics Board Member & Executive Vice President 000 0000
Peter Corr Ph.D Auven Therapeutics Board Member 000 0000
Peter Hug Ph.D ADC Therapeutics Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

ADC Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ADC Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ADC Therapeutics‘s full profile, request access.

Request a free trial

ADC Therapeutics Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 14-Dec-2020 00000 0000 Drug Discovery 00000 000
To view ADC Therapeutics’s complete investments history, request access »